April 5, 2024

Dear Community,

We are writing today to provide you with an update on the status of our PrProfile study (NCT06153966). PrProfile is a Phase 1/2a clinical trial to evaluate our investigational drug, ION717, in people with symptomatic prion disease.

Due to exceptionally fast enrollment, we have reached capacity at the current stage of the trial, and we will, per the study’s design, be pausing recruitment to complete this stage of the trial. The pause does not impact any participants who are currently enrolled or undergoing screening. Individuals who are currently enrolled will continue with all regularly scheduled trial-related visits, and individuals who have already been accepted by a site for screening will continue to advance through that process and be enrolled if they meet the study’s eligibility requirements.

Per the study design, and as is common in first-in-human clinical trials like this one, data from people enrolled early in the trial must be collected and reviewed prior to enrolling additional people into PrProfile. When we initiated this clinical trial, we anticipated recruitment would be slow, which would allow us more time to complete the required data collection and review prior to reaching enrollment capacity for this stage of the trial. Our assumptions were incorrect; recruitment has been rapid. As a result, we have reached capacity at the current stage of the trial and therefore recruitment will be paused at all trial sites.

For clarity, the pause does not mean that enrollment in PrProfile has been completed or that the trial is ending. It is not the result of observations or data collected in the study to date, nor has this pause been requested by any regulator or monitoring body.

The rapid enrollment further reinforces our belief of the need for scientific research to discover and develop medicines for this population, and we are committed to working steadfastly to complete the necessary steps to re-open recruitment. As part of the Ionis commitment to transparency, we will update the status of the trial on clinicaltrials.gov to “Active, not recruiting”. This update will appear on the clinicaltrials.gov posting soon. Once the data have been reviewed, we expect that enrollment will reopen later this year at which time we will update the status of the trial on clinicaltrials.gov back to "Recruiting".

We acknowledge the people with prion disease who have enrolled in PrProfile so far and thank them and their caregivers for their ongoing contributions and collaboration. We recognize the urgent need for advancing treatments and remain dedicated to the prion disease community. We will provide the prion disease community with updates as appropriate in the future.

Sincerely,

The Ionis ION717 Team

Below is additional information you may find helpful:
Does this pause impact people already enrolled or in the screening process for PrProfile?

No. People who have already been enrolled or are already in the screening process will not be impacted by this recruitment pause. They will continue to advance through trial procedures without interruption.

What is the purpose of the planned data review?

The required data collection and review that will occur during the recruitment pause will be used to inform appropriate next steps regarding exposing additional people to the investigational drug being tested in this study, ION717. This data review is not designed to provide any conclusions about safety and efficacy of ION717. Data reviews of this nature are common in early-stage clinical trials like PrProfile.

Will there be additional recruitment pauses?

We do not anticipate additional protracted global recruitment pauses will be required during this trial. We will update the prion disease community regarding any changes to the trial’s status.

What should other people who are interested in participating in PrProfile do now?

Individuals interested in participating in PrProfile should discuss it with their doctor. Individuals may also call +1-844-221-3587 or email PrionDisease@clinicaltrialmedia.com to be informed of any future changes to the study’s recruitment status.

Is there a way to receive ION717 outside the clinical trial, such as for people not eligible for this clinical trial?

Evaluation of the safety and efficacy of ION717 in clinical trials is essential to establishing whether ION717 can help people diagnosed with symptomatic prion disease. For this reason, ION717 is not available outside this clinical trial. We are working diligently to conduct the clinical trials necessary to evaluate ION717 in individuals with symptomatic prion disease. For additional information about Ionis’ expanded access policy, which also includes Right To Try and Compassionate Use, click here.

Will the recruitment pause affect how long it will take to complete PrProfile?

At this time, we don’t anticipate that the recruitment pause will impact the overall timeline for completing the study. PrProfile will conclude after all participants complete all study procedures and study visits, as outlined in the clinical trial protocol. Ionis will utilize Clinicaltrials.gov to communicate updates regarding the study’s status and anticipated completion dates. However, the study's timeline largely depends on how long it takes to complete total enrollment. Therefore, the posted dates are subject to change.

The CJD Foundation (US) and CJD International Support Alliance are community resources that provide education and support to those affected by prion disease.

For more information about Ionis, visit www.ionispharma.com or email padvocacy@ionisph.com.